论文部分内容阅读
目的 探讨低分子肝素治疗TIA的疗效及安全性。 方法 采用随机分组 ,将所观察的 5 0例TIA病人分为治疗组 :低分子肝素 (速避凝 ,法国塞诺菲温莎公司生产 ) 0 4ml腹部脐旁两侧皮下注射每 12小时一次 ;对照组 :5 %葡萄糖注射液或生理盐水 2 5 0ml+丹参液 2 0ml静脉点滴及肠溶阿斯匹林片 75mg每日一次口服。观察临床疗效及治疗前后实验室指标与副作用 ,并将有关数据进行统计处理。 结果 低分子肝素治疗TIA临床疗效优于对照组 (P<0 0 1) ,实验室指标治疗前后无显著差异 (P >0 0 5 ) ,且副作用小。 结论 低分子肝素治疗TIA效果好 ,较安全
Objective To investigate the efficacy and safety of low molecular weight heparin in the treatment of TIA. Methods Fifty TIA patients were divided into treatment group and randomized control group. Low molecular weight heparin (contraceptive coagulation, manufactured by Sanofi-Windsor, France) was injected subcutaneously on both sides of the umbilical cord every 24 hours. Control Group: 5% glucose injection or saline 250ml + Danshen solution 20ml intravenous and enteric-coated aspirin tablets 75mg orally once daily. Observed the clinical curative effect and the laboratory index and the side effect before and after the treatment, and the related data carries on the statistical processing. Results The clinical efficacy of low molecular weight heparin in the treatment of TIA was better than that of the control group (P <0.01). There was no significant difference in the laboratory indexes before and after treatment (P> 0.05) and the side effects were small. Conclusion Low molecular weight heparin is effective and safe for the treatment of TIA